slno,preds
0,"To determine if the patient will survive after 2.48 years based on the provided pathology report, we need to analyze several key factors:

1. **Tumor Characteristics**: The report indicates two distinct adenocarcinomas: one measuring 1 cm and the other 3.5 cm. Both tumors have free surgical margins, which is a positive sign as it suggests that the tumors were completely removed during surgery.

2. **Lymph Node Involvement**: Importantly, there is no lymph node metastasis reported. This is a critical factor because the absence of metastasis generally correlates with a better prognosis.

3. **Molecular Studies**: The presence of a positive KRAS mutation is noted. KRAS mutations are often associated with a poorer prognosis in lung adenocarcinomas. However, the absence of EGFR mutations is also mentioned, which is relevant since EGFR mutations can sometimes be targeted with specific therapies that improve outcomes.

4. **Morphological Distinction**: The tumors are described as morphologically distinct, suggesting they may be separate primary cancers. This could complicate the prognosis, but the fact that they are both localized and have free margins is favorable.

5. **Additional Findings**: The presence of emphysema is noted, which can complicate lung function and overall health but does not directly impact the prognosis of the tumors themselves.

Considering these factors, while the presence of the KRAS mutation is concerning, the overall picture of localized disease with no lymph node involvement and free margins suggests a potentially favorable outcome. Therefore, it is reasonable to conclude that the patient has a chance of survival after 2.48 years.

Answer - {""Survival"": ""True""}"
1,"To determine if the patient will survive after 2.48 years based on the provided pathology report, we need to analyze the key findings:

1. **Tumor Characteristics**: The report indicates a moderately differentiated adenocarcinoma measuring 2.0 x 2.0 x 1.6 cm. The size of the tumor is significant, but it is classified as T2, which indicates a tumor size greater than 3 cm but less than or equal to 5 cm. However, in this case, the tumor is actually smaller than 3 cm, which may suggest a lower stage than T2.

2. **Lymph Node Involvement**: The report states that multiple lymph nodes were biopsied and all were negative for neoplasm. This is a positive indicator as it suggests that the cancer has not spread to the lymphatic system, which is crucial for prognosis.

3. **Pleural Invasion**: There is focal pleural invasion noted, which can be concerning as it indicates that the tumor has begun to invade surrounding structures. However, the absence of lymphovascular space invasion is a favorable factor.

4. **Final Staging**: The final staging is T2N0, which indicates that while there is a tumor present (T2), there is no regional lymph node involvement (N0). This is a relatively favorable staging compared to more advanced stages where lymph nodes are involved.

Considering these factors, the absence of lymph node involvement and the relatively small size of the tumor (despite the pleural invasion) suggest a better prognosis. Patients with T2N0 lung cancer generally have a reasonable chance of survival, especially with appropriate treatment.

Based on this analysis, the conclusion is that the patient is likely to survive after 2.48 years.

Answer - {""Survival"": ""True""}"
2,"To determine if the patient will survive after 2.48 years based on the provided pathology report, we need to analyze the key findings:

1. **Tumor Characteristics**: The tumor is described as adenocarcinoma with a lepidic pattern, which is typically associated with a better prognosis. It measures 2.8 cm and is well-differentiated, indicating that the cancer cells are more similar to normal cells and tend to grow more slowly.

2. **Invasiveness**: The report states that the tumor is minimally invasive, which is a positive sign as it suggests that the cancer has not spread extensively beyond its original site.

3. **Surgical Margins**: The surgical margins are negative, meaning that no cancer cells were found at the edges of the removed tissue. This is crucial as it indicates that the tumor has been completely excised.

4. **Lymphovascular Invasion**: There is no evidence of lymphovascular invasion, which reduces the likelihood of the cancer spreading to lymph nodes or other parts of the body.

5. **Lymph Node Examination**: The lymph node examinations showed no malignancy in the sampled nodes, which is a strong indicator that the cancer has not metastasized.

6. **Staging**: The cancer is staged as pT1b, pN1. The T1b classification indicates a small tumor size (2.8 cm), and pN1 suggests that there may be some involvement of nearby lymph nodes, but since they are negative for malignancy, this is less concerning.

Given these factors, the overall prognosis appears favorable. The well-differentiated nature of the tumor, the absence of invasive characteristics, negative margins, and no lymph node involvement suggest a high likelihood of survival.

Based on this analysis, the answer is:

{""Survival"": ""True""}"
3,"To determine if the patient will survive after 2.48 years based on the provided pathology report, we need to analyze the key findings:

1. **Tumor Characteristics**: The tumor is described as moderately-poorly differentiated adenocarcinoma, which generally indicates a more aggressive behavior compared to well-differentiated tumors.

2. **Tumor Size**: The maximum tumor size is 2.5 x 2.0 cm. While this size is relatively small, the differentiation and other factors are more critical in assessing prognosis.

3. **Lymph Node Involvement**: Out of twelve examined lymph nodes, ten are involved with metastatic carcinoma, including the subcarinal lymph node. This high rate of lymph node involvement is a significant negative prognostic factor, as it suggests that the cancer has spread beyond the primary site.

4. **Surgical Margins**: The surgical margins are negative for tumor, which is a positive aspect, indicating that the tumor was likely completely resected. However, this is somewhat overshadowed by the extensive lymph node involvement.

5. **Lymphovascular Invasion**: The presence of extensive lymphovascular invasion is concerning, as it indicates that cancer cells may have invaded the lymphatic and blood vessels, increasing the likelihood of metastasis and recurrence.

Considering these factors, the extensive lymph node involvement and lymphovascular invasion suggest a poor prognosis. The presence of ten involved lymph nodes is particularly alarming and indicates a higher risk of disease progression.

Based on this analysis, it is reasonable to conclude that the patient is unlikely to survive after 2.48 years due to the aggressive nature of the disease and the significant metastatic spread.

Answer - {""Survival"": ""False""}"
4,"To determine if the patient will survive after 2.48 years based on the provided pathology report, we need to analyze the key findings:

1. **Tumor Characteristics**: The tumor is described as an invasive poorly differentiated adenocarcinoma measuring 2.7 cm. Poorly differentiated tumors generally have a worse prognosis compared to well-differentiated tumors.

2. **Invasion**: The tumor is noted to invade the visceral pleura, which is a concerning feature as it indicates a more aggressive disease. Additionally, there is intratumoral large vessel invasion, which further suggests a higher risk of metastasis and poorer outcomes.

3. **Lymph Node Involvement**: The level 5 lymph node resection revealed two anthracotic lymph nodes that were negative for metastatic carcinoma. This is a positive finding, as it indicates that there is no lymphatic spread to these nodes.

4. **Pleural Biopsy**: The left pleural biopsy showed chronic inflammation but was negative for carcinoma, which is also a favorable finding as it suggests that the cancer has not spread to the pleura.

5. **Staging**: The tumor is staged as pT2a, which indicates a tumor size of 2-5 cm with local invasion but no distant metastasis identified. This stage suggests that the cancer is still localized, which is a better prognostic factor.

6. **Margins**: The report does not specify the exact status of surgical margins, but the absence of distant metastasis is a positive sign.

Considering these factors, while the tumor is poorly differentiated and has some aggressive features (visceral pleural invasion and large vessel invasion), the absence of lymph node involvement and distant metastasis are significant positive indicators for survival.

Based on this analysis, the prognosis is cautiously optimistic, and the patient may have a chance of survival after 2.48 years.

Answer - {""Survival"": ""True""}"
5,"To determine if the patient will survive after 2.48 years based on the provided pathology report, we need to analyze several key factors:

1. **Tumor Type and Size**: The patient has invasive mucinous adenocarcinoma measuring 2.5 cm. Mucinous adenocarcinomas can have variable behavior, but the size is relatively small.

2. **Margins**: The report states that there are clear margins following a completion lobectomy, which is a positive indicator as it suggests that the tumor has been completely removed and there is no residual disease.

3. **Lymph Node Involvement**: All examined lymph nodes (levels 4, 7, and 10) were negative for carcinoma. This indicates that there is no regional lymph node metastasis, which is a favorable prognostic factor.

4. **Molecular Studies**: The presence of a KRAS mutation (p.G12C) is noted, which is associated with a potential for poor prognosis and resistance to certain therapies. However, the absence of EGFR mutations is also mentioned, which may influence treatment options.

5. **Overall Assessment**: Despite the presence of a KRAS mutation, the clear surgical margins and negative lymph nodes are strong indicators of a better prognosis. The tumor's small size and the absence of metastasis are significant positive factors.

Considering these points, the overall prognosis appears to be favorable despite the KRAS mutation. Therefore, it is reasonable to conclude that the patient has a good chance of survival after 2.48 years.

Answer - {""Survival"": ""True""}"
6,"To determine if the patient will survive after 2.48 years based on the provided pathology report, we need to analyze the key findings:

1. **Tumor Characteristics**: The report indicates an invasive grade 3 adenocarcinoma in the right lower lobe, measuring 5 x 4 x 3 cm. Grade 3 tumors are typically poorly differentiated, which is associated with a worse prognosis.

2. **Lymph Node Involvement**: One of six intrapulmonary peribronchial lymph nodes tested positive for metastatic adenocarcinoma. The presence of metastasis in lymph nodes is a significant factor that negatively impacts survival.

3. **Margins**: The bronchial margins are reported as negative, which is a positive aspect, indicating that the tumor has not invaded the bronchial tissue.

4. **Additional Findings**: The wedge excision of the right upper lobe showed necrotizing granuloma, which is not related to the malignancy. The mediastinal lymph nodes showed necrotizing granulomatous lymphadenitis but were negative for tumor, which suggests that while there is inflammation, it does not indicate further spread of cancer.

Considering the aggressive nature of grade 3 adenocarcinoma and the presence of metastasis in at least one lymph node, the prognosis is likely poor. The combination of these factors suggests a higher risk of disease progression and lower chances of survival over the specified time frame.

Based on this analysis, the conclusion is that the patient is unlikely to survive after 2.48 years.

Answer - {""Survival"": ""False""}"
7,"To determine if the patient will survive after 2.48 years based on the provided pathology report, we can analyze the key findings:

1. **Tumor Characteristics**: The tumor is described as moderately differentiated adenocarcinoma measuring 2.3 cm. This size indicates a relatively small tumor, which is generally associated with a better prognosis.

2. **Extent of Disease**: The carcinoma extends to within 1 mm of the staple line but does not invade the visceral pleura. This suggests that while there is some proximity to surgical margins, there is no direct invasion into surrounding structures, which is a positive sign.

3. **Lymph Node Involvement**: Importantly, no metastatic carcinoma was identified in the examined lymph nodes. This is a critical factor, as the absence of lymph node involvement (N0) indicates that the cancer has not spread beyond the primary site.

4. **Staging**: The final staging is pT1b N0, which classifies the tumor as localized (T1b) without lymph node involvement (N0). This staging is associated with a favorable prognosis.

5. **Clinical Correlation and Follow-Up**: The recommendation for clinical correlation and follow-up suggests that the medical team is optimistic about monitoring the patient's condition, which is another positive indicator.

Considering these factors, the prognosis appears to be favorable due to the localized nature of the disease, absence of lymph node involvement, and the relatively small size of the tumor.

Based on this analysis, it is reasonable to conclude that the patient is likely to survive after 2.48 years.

Answer - {""Survival"": ""True""}"
8,"To determine if the patient will survive after 2.48 years based on the provided pathology report, we need to analyze the key findings:

1. **Tumor Characteristics**: The report indicates that the patient has invasive moderately differentiated adenocarcinoma in the right upper lobe. The differentiation of the tumor is moderate, which is generally associated with a better prognosis compared to poorly differentiated tumors.

2. **Lymph Node Involvement**: There is metastatic involvement in one of four hilar lymph nodes. While lymph node involvement is a negative prognostic factor, having only one involved lymph node out of four examined is relatively favorable.

3. **Surgical Margins**: The surgical margins, including the bronchial resection margin, are negative for carcinoma. This is a positive indicator as it suggests that the tumor was completely resected, reducing the risk of local recurrence.

4. **Pleural Involvement and Angiolymphatic Invasion**: There is no evidence of pleural involvement or angiolymphatic invasion. The absence of these factors is significant as they are associated with a higher risk of metastasis and poorer outcomes.

Considering these points, the presence of only one involved lymph node, negative surgical margins, and no pleural or angiolymphatic invasion suggests a more favorable prognosis. Therefore, it is reasonable to conclude that the patient has a good chance of survival after 2.48 years.

Answer - {""Survival"": ""True""}"
9,"To determine if the patient will survive after 2.48 years based on the provided pathology report, we need to analyze the key findings:

1. **Tumor Characteristics**: The tumor is described as an invasive well-differentiated adenocarcinoma with a predominant bronchiolo-alveolar carcinoma component. Well-differentiated tumors generally have a better prognosis compared to poorly differentiated ones.

2. **Size of the Tumor**: The tumor measures approximately 50 x 60 x 45 mm, which is relatively large. However, the differentiation and lack of aggressive features are more critical in assessing prognosis.

3. **Invasion and Metastasis**: There is no evidence of vascular or perineural invasion, which are indicators of a more aggressive disease. Additionally, there are no metastases to the hilar lymph nodes, which is a positive sign.

4. **Pleural Involvement**: The tumor closely abuts the pleural surface, but confirmatory stains suggest that the pleura is likely not involved. This is significant because pleural involvement can worsen the prognosis.

5. **Additional Findings**: The presence of a separate specimen showing features consistent with a lipoma, with no evidence of malignancy, indicates that there are no additional malignancies complicating the patient's condition.

Considering these factors, the absence of aggressive features, lack of metastasis, and well-differentiated nature of the tumor suggest a favorable prognosis. Therefore, it is reasonable to conclude that the patient has a good chance of survival after 2.48 years.

Answer - {""Survival"": ""True""}"
10,"To determine if the patient will survive after 2.48 years based on the provided pathology report, we need to analyze the key findings:

1. **Tumor Characteristics**: The tumor is described as poorly differentiated adenocarcinoma, which generally indicates a more aggressive behavior compared to well-differentiated tumors.

2. **Tumor Size**: The tumor measures 3 x 3 x 3 cm. Tumor size can be an important factor in prognosis, with larger tumors often associated with worse outcomes.

3. **Invasion**: The tumor has invaded the visceral pleura. Pleural invasion is a significant factor that can indicate a higher risk of metastasis and poorer prognosis.

4. **Lymph Node Involvement**: There is metastasis in 1 out of 1 examined lymph node. The presence of lymph node metastasis is a critical prognostic factor, as it suggests that the cancer has spread beyond the primary site.

5. **Immunohistochemical Staining**: The immunohistochemical profile shows positivity for markers typically associated with lung adenocarcinoma (CD15, CK7, TTF1, CEA) and negativity for markers associated with colorectal cancer (CK20, CDX2). While this helps confirm the diagnosis, it does not directly influence survival.

Given these factors, the presence of poorly differentiated adenocarcinoma, visceral pleural invasion, and lymph node metastasis suggests a more advanced stage of disease, which is typically associated with a poorer prognosis.

Based on this analysis, it is likely that the patient will not survive after 2.48 years.

Answer - {""Survival"": ""False""}"
11,"To determine if the patient will survive after 2.48 years based on the provided pathology report, we need to analyze the key findings:

1. **Tumor Size and Type**: The tumor is located in the left lower lobe and measures 4.0 x 3.5 x 2.0 cm. It is diagnosed as adenocarcinoma of mixed subtype, predominantly papillary. The size and subtype can influence prognosis, with papillary adenocarcinomas generally having a better prognosis than poorly differentiated types.

2. **Invasion**: The report indicates infiltration of the visceral pleura. This is significant because pleural invasion can suggest a higher risk of metastasis and poorer prognosis.

3. **Pathological Classification**: The tumor is classified as pT2, which indicates a tumor size greater than 3 cm but less than or equal to 5 cm. This classification is important for staging and prognosis.

4. **Lymph Node Involvement**: There is no regional lymph node involvement (0/20 lymph nodes examined), which is a positive sign and suggests that the cancer has not spread to nearby lymph nodes.

5. **Distant Metastasis Status**: The distant metastasis status is unknown (pMx). This uncertainty can complicate the prognosis, as undetected metastasis could significantly affect survival.

6. **Tumor Grade**: The tumor grade is G2, indicating moderate differentiation. Generally, well-differentiated tumors have a better prognosis than poorly differentiated ones.

Considering these factors, the presence of pleural invasion raises concern for potential metastasis, but the absence of lymph node involvement is a favorable sign. The unknown status of distant metastasis adds uncertainty to the prognosis.

Overall, while there are concerning features (pleural invasion and unknown distant metastasis), the lack of lymph node involvement and moderate differentiation suggest that the patient may have a reasonable chance of survival over the specified time frame.

Based on this analysis, the final answer is:

{""Survival"": ""True""}"
12,"To determine if the patient will survive after 2.48 years based on the provided pathology report, we need to analyze the key findings:

1. **Tumor Characteristics**: The tumor is a moderately differentiated adenocarcinoma measuring 2.7 cm. The differentiation suggests that the tumor is not poorly differentiated, which is generally associated with a better prognosis.

2. **Invasion and Margins**: There is no angiolymphatic invasion or pleural involvement, which are positive indicators for survival. Additionally, the bronchial margin is negative, meaning there is no tumor at the resection edge, reducing the risk of local recurrence.

3. **Lymph Node Involvement**: Metastatic adenocarcinoma was found in 1 out of 4 peribronchial lymph nodes. While there is some lymph node involvement, the number of affected nodes is relatively low, and there are no metastases in the R4 and station 11 lymph nodes, which is a favorable sign.

4. **Overall Assessment**: The absence of angiolymphatic invasion, pleural involvement, and negative surgical margins, combined with limited lymph node involvement, suggests a better prognosis. 

Considering these factors, the overall assessment leans towards a favorable outcome for the patient.

Answer - {""Survival"": ""True""}"
13,"To determine if the patient will survive after 2.48 years based on the provided pathology report, we need to analyze the key findings:

1. **Tumor Size and Differentiation**: The tumor is 1.2 cm in size and is classified as moderately to poorly differentiated. Smaller tumors generally have a better prognosis, but the differentiation grade can impact the aggressiveness of the cancer.

2. **Surgical Margins**: All surgical margins are free of tumor, which is a positive indicator as it suggests that the tumor was completely removed during surgery.

3. **Visceral Pleural Invasion**: There is focal invasion into the visceral pleura. While this indicates a more aggressive behavior, it is focal and not extensive, which may still allow for a favorable outcome.

4. **Lymphatic Invasion**: There is a focus suggestive of lymphatic invasion, but it is not confirmed as lymph node involvement is absent among the seven examined nodes. This is crucial because the absence of lymph node metastasis is a strong positive prognostic factor.

5. **Further Testing**: The recommendation for mutation analysis for EGFR and KRAS suggests that there may be targeted therapy options available, which could improve the patient's prognosis.

Considering these factors, the absence of lymph node involvement and the fact that the tumor is relatively small and has clear surgical margins are significant positive indicators for survival. The focal pleural invasion and lymphatic invasion are concerning but do not outweigh the positive aspects.

Based on this analysis, the patient has a reasonable chance of survival after 2.48 years.

Answer - {""Survival"": ""True""}"
14,"To determine if the patient will survive after 2.48 years based on the provided pathology report, we need to analyze the key findings:

1. **Tumor Characteristics**: The tumor is an acinar type adenocarcinoma, grade III, which indicates a poorly differentiated cancer. Poorly differentiated tumors generally have a worse prognosis compared to well-differentiated tumors.

2. **Tumor Size and Invasion**: The tumor measures 4 cm and invades the visceral pleura. Visceral pleural invasion is a concerning feature as it suggests a more aggressive disease and potential for metastasis.

3. **Lymph Node Involvement**: Metastatic adenocarcinoma was found in 2 out of 4 lymph nodes examined. The presence of metastasis in lymph nodes (N2 stage) indicates that the cancer has spread beyond the primary site, which is a significant factor in determining prognosis.

4. **Staging**: The report concludes with a staging of pT2, N2, Mx. The T2 classification indicates a tumor size of 3-5 cm, and N2 indicates involvement of lymph nodes that are not directly adjacent to the primary tumor. The Mx indicates that distant metastasis has not been assessed.

Given these factors, the presence of a poorly differentiated tumor, visceral pleural invasion, and lymph node metastasis suggests a more advanced stage of cancer with a poorer prognosis. 

Considering these points, it is likely that the patient may not survive after 2.48 years due to the aggressive nature of the disease and the presence of metastasis.

Answer - {""Survival"": ""False""}"
15,"To determine if the patient will survive after 2.48 years based on the provided pathology report, we need to analyze the key findings:

1. **Tumor Characteristics**: The report indicates an invasive moderately differentiated adenocarcinoma measuring 9.2 cm. The size of the tumor is significant, as larger tumors generally correlate with a worse prognosis.

2. **Invasion**: The tumor has invaded the chest wall, which is a critical factor. Tumors that invade surrounding structures typically indicate a more advanced stage of cancer and can lead to a poorer prognosis.

3. **Margins**: The report states that the surgical margins are negative for carcinoma, which is a positive aspect. Negative margins suggest that the tumor has been completely removed, reducing the risk of local recurrence.

4. **Lymph Node Involvement**: Importantly, the report mentions that multiple lymph nodes and a peribronchial biopsy from the right side are negative for carcinoma, with no evidence of malignancy found in 19 examined peribronchial lymph nodes. This is a favorable finding, as it indicates that the cancer has not spread to the lymph nodes, which is often a critical factor in determining prognosis.

5. **Pathological Staging**: The tumor is classified as pT3, which indicates a locally advanced tumor. While this is concerning, the absence of lymph node involvement is a significant positive factor.

Considering these points, the presence of a large tumor with chest wall invasion (pT3) is concerning for survival, but the lack of lymph node involvement and negative margins provide some hope. However, the overall prognosis is likely to be guarded due to the tumor's size and invasion characteristics.

Based on the analysis, the final determination is that the patient is unlikely to survive after 2.48 years due to the aggressive nature of the tumor and its local invasion.

Answer - {""Survival"": ""False""}"
16,"To determine if the patient will survive after 2.48 years based on the provided pathology report, we need to analyze the key findings:

1. **Diagnosis**: The patient has a diagnosis of moderately differentiated adenocarcinoma in the left lower lobe, measuring 6.9 cm. This is a significant tumor size, which is a concerning factor for prognosis.

2. **Invasion**: The tumor shows visceral pleural invasion and lymphangitic invasion. Visceral pleural invasion indicates a more aggressive tumor behavior and can be associated with a higher risk of metastasis.

3. **Lymph Node Involvement**: There is metastatic adenocarcinoma identified in multiple lymph nodes (one from left level 9 and two out of five from left level 11). The presence of metastasis in lymph nodes is a critical factor that negatively impacts survival.

4. **Absence of Distant Metastasis**: While there is no evidence of distant metastasis noted, the presence of regional lymph node involvement is still a significant concern.

Given these factors, the presence of a large tumor with visceral pleural invasion and multiple lymph node metastases suggests a poor prognosis. The combination of these findings typically indicates a higher likelihood of disease progression and lower survival rates.

Based on this analysis, the conclusion is that the patient is unlikely to survive after 2.48 years.

Answer - {""Survival"": ""False""}"
17,"Reasoning Steps:
1. The pathology report does not provide any specific diagnostic information about the tumor type, its size, grade, or any involvement of lymph nodes or margins.
2. Without any details regarding the tumor characteristics, it is impossible to assess the prognosis or survival chances of the patient.
3. The lack of information means we cannot determine whether the patient has a favorable or unfavorable prognosis.

Answer - {""Survival"": ""False""}"
18,"To determine if the patient will survive after 2.48 years based on the provided pathology report, we need to analyze the key findings:

1. **Tumor Type and Differentiation**: The tumor is a well-differentiated papillary non-mucinous adenocarcinoma, which is generally associated with a better prognosis compared to poorly differentiated tumors.

2. **Tumor Size and Location**: The tumor measures 50 mm (5 cm) and is located in the right lower lobe. It is classified as pT2, indicating a tumor size greater than 3 cm but less than or equal to 5 cm.

3. **Pleural Involvement**: The tumor extends to the visceral pleura, but the pleura is tumor-free. This suggests that while there is some local invasion, it has not penetrated the pleura, which is a positive sign.

4. **Lymph Node Involvement**: The report indicates pN0, meaning there is no lymph node involvement. This is a critical factor as the absence of lymph node metastasis significantly improves the prognosis.

5. **Distant Metastasis**: The report states pMX, indicating that distant metastasis cannot be assessed, but there is no evidence of metastasis mentioned.

6. **Surgical Margins**: The resection margins are clear of tumor (R0), which is an excellent indicator of a successful surgical outcome and reduces the risk of local recurrence.

7. **Overall Staging**: The tumor is classified as stage I B, which typically has a favorable prognosis, especially with well-differentiated tumors and no lymph node involvement.

Considering all these factors, the prognosis appears to be favorable. The well-differentiated nature of the tumor, absence of lymph node involvement, clear surgical margins, and the fact that it is at an early stage (I B) all suggest a higher likelihood of survival.

Based on this analysis, the answer is:

{""Survival"": ""True""}"
19,"To determine if the patient will survive after 2.48 years based on the provided pathology report, we need to analyze the key findings:

1. **Tumor Characteristics**: The report indicates a poorly differentiated adenocarcinoma measuring 4.5 cm. Poorly differentiated tumors generally have a worse prognosis compared to well-differentiated tumors.

2. **Invasion**: There is visceral pleural invasion and lymphovascular invasion noted. The presence of these invasions suggests a higher likelihood of metastasis and a more aggressive disease course.

3. **Lymph Node Involvement**: One of the six lymph nodes examined contains metastatic carcinoma with extracapsular extension. Extracapsular extension is a significant negative prognostic factor, indicating a higher risk of systemic spread.

4. **Staging**: The tumor is staged as pT2aN1MX. The presence of N1 indicates that there is regional lymph node involvement, which typically correlates with a poorer prognosis.

Considering these factors, the presence of poorly differentiated adenocarcinoma, visceral pleural invasion, lymphovascular invasion, and positive lymph nodes with extracapsular extension suggests a high risk of disease progression and a lower likelihood of survival over the specified time frame.

Based on this analysis, the conclusion is that the patient is unlikely to survive after 2.48 years.

Answer - {""Survival"": ""False""}"
20,"To determine if the patient will survive after 2.48 years based on the provided pathology report, we need to analyze the key elements of the report:

1. **Tumor Type**: The report indicates a poorly differentiated bronchiolo-alveolar adenocarcinoma. Poorly differentiated tumors generally have a worse prognosis compared to well-differentiated tumors.

2. **Tumor Size**: The tumor measures 2.5 x 1.5 x 3 cm. While the size is not excessively large, the differentiation grade is more critical in this context.

3. **Lymph Nodes and Invasion**: The report does not provide any information regarding lymph node involvement or vascular invasion. The absence of this information is concerning because lymph node involvement is a significant factor in determining prognosis.

4. **Lack of Additional Findings**: The report does not mention any additional findings that could provide more context about the tumor's behavior or the patient's overall condition.

Given the poorly differentiated nature of the adenocarcinoma and the lack of information regarding lymph node involvement or other critical factors, it is reasonable to conclude that the prognosis is likely poor.

Based on these considerations, the final answer is:

{""Survival"": ""False""}"
21,"To determine if the patient will survive after 2.48 years based on the provided pathology report, we need to analyze the key findings:

1. **Tumor Characteristics**: The tumor is a moderately differentiated adenocarcinoma measuring 2.5 cm. The size is relatively small, which is a positive factor for prognosis.

2. **Margins**: The report states that the surgical margins are negative, indicating that the tumor has been completely excised without any cancer cells at the edges of the removed tissue. This is a favorable sign.

3. **Invasion**: There is mention of invasion towards the pleural surface, but it does not directly involve the visceral pleura. This suggests that while there is some degree of local invasion, it has not penetrated into the pleura, which is a critical factor in staging and prognosis.

4. **Lymph Nodes**: All examined regional lymph nodes (five in total) and the fat pad biopsy were negative for malignancy. This is a significant positive indicator, as the absence of metastatic disease in lymph nodes suggests that the cancer has not spread beyond the primary site.

5. **Overall Assessment**: Given the small size of the tumor, negative margins, absence of vascular or lymphatic invasion, and negative lymph nodes, the overall prognosis appears to be favorable. The absence of metastasis and the lack of direct pleural involvement further support a better survival outlook.

Based on these considerations, it is reasonable to conclude that the patient has a good chance of survival after 2.48 years.

Answer - {""Survival"": ""True""}"
22,"To determine if the patient will survive after 2.48 years based on the provided pathology report, we need to analyze the key findings:

1. **Tumor Characteristics**: The report indicates a poorly differentiated adenocarcinoma in the right upper lobe, measuring 1.7 cm. Poorly differentiated tumors generally have a worse prognosis compared to well-differentiated tumors.

2. **Metastatic Involvement**: There is evidence of metastatic carcinoma in multiple lymph nodes, specifically at levels 7 and 12. The presence of metastasis in lymph nodes is a significant factor that negatively impacts survival.

3. **Capsular Penetration and Lymphatic Invasion**: The report mentions capsular penetration and lymphatic invasion, which are indicators of aggressive disease and further suggest a higher likelihood of metastasis and poorer outcomes.

4. **Surgical Margins**: Although the surgical margins are negative for carcinoma, which is a positive aspect, the presence of metastasis in lymph nodes and the characteristics of the tumor overshadow this finding.

Considering these factors, the presence of poorly differentiated adenocarcinoma with lymph node metastasis and evidence of aggressive features suggests a poor prognosis. Therefore, it is likely that the patient will not survive after 2.48 years.

Answer - {""Survival"": ""False""}"
23,"To determine if the patient will survive after 2.48 years based on the provided pathology report, we need to analyze the key findings:

1. **Tumor Characteristics**: The report indicates a moderately differentiated adenocarcinoma measuring 2.0 cm in the right upper lobe. The size of the tumor is relatively small, which is generally a positive prognostic factor.

2. **Surgical Margins**: The report states that the surgical margins are clear, meaning that there is no residual cancer at the edges of the excised tissue. Clear margins are associated with a lower risk of local recurrence.

3. **Lymph Node Involvement**: The lymph nodes examined from various levels, including level IX and level XI, are negative for malignancy. This indicates that there is no evidence of metastasis to the lymph nodes, which is a critical factor in determining prognosis.

4. **Pleural Involvement**: There is no pleural involvement noted in the report. This further supports the idea that the cancer is localized and has not spread to surrounding tissues.

Based on these findings, the patient has a localized lung adenocarcinoma with no evidence of metastasis, clear surgical margins, and negative lymph nodes. These factors suggest a favorable prognosis.

Therefore, the conclusion is that the patient is likely to survive after 2.48 years.

Answer - {""Survival"": ""True""}"
24,"To determine if the patient will survive after 2.48 years based on the provided pathology report, we need to analyze the key findings:

1. **Tumor Size and Type**: The tumor is classified as adenocarcinoma, measuring 6.5 x 6.5 x 5.0 cm, which is relatively large. The classification as pT2b indicates a tumor size greater than 5 cm but less than or equal to 7 cm.

2. **Lymph Node Involvement**: The report indicates pN1 with 6 out of 28 lymph nodes involved. This suggests that there is significant lymph node metastasis, which is a concerning factor for prognosis.

3. **Pleural Invasion**: There is no infiltration of the visceral pleura, which is a positive aspect as it may indicate a lower risk of further spread.

4. **Grade and Proliferation Index**: The tumor is classified as G3, indicating a poorly differentiated tumor. The Ki-67 proliferation index of 40% is relatively high, suggesting a more aggressive tumor with a higher likelihood of growth and spread.

Considering these factors, the presence of multiple involved lymph nodes (6 out of 28) and the high-grade nature of the tumor (G3) are significant indicators of a poor prognosis. While the absence of pleural invasion is favorable, the overall picture suggests that the patient may have a challenging prognosis.

Based on this analysis, it is reasonable to conclude that the patient may not survive after 2.48 years.

Answer - {""Survival"": ""False""}"
25,"To determine if the patient will survive after 2.48 years based on the provided pathology report, we need to analyze the key findings:

1. **Diagnosis**: The patient has metastatic adenocarcinoma, which indicates that the cancer has spread beyond its original site. This is a significant factor in prognosis.

2. **Lymph Node Involvement**: Eight out of twelve lymph nodes are positive for cancer, which suggests a high burden of disease. The presence of cancer in multiple lymph nodes is associated with a poorer prognosis.

3. **Tumor Characteristics**: The tumor is described as moderately to poorly differentiated, which typically indicates a more aggressive form of cancer. The size of the tumor (5.0 x 4.1 x 2.4 cm) also suggests a significant mass.

4. **Lymphovascular Invasion**: The report mentions lymphovascular invasion, which is a sign that the cancer may be spreading through the lymphatic system or blood vessels, further complicating the prognosis.

5. **Direct Extension**: The tumor has direct extension into two intraparenchymal lymph nodes, indicating local spread of the cancer.

6. **Molecular Analysis**: The absence of EGFR mutations may limit treatment options, as certain targeted therapies are not applicable. The presence of a polymorphism of uncertain clinical significance does not provide clear guidance for treatment.

Given these factors, the presence of metastatic disease, significant lymph node involvement, and aggressive tumor characteristics suggest a poor prognosis. Therefore, it is unlikely that the patient will survive after 2.48 years.

Answer - {""Survival"": ""False""}"
26,"To determine if the patient will survive after 2.48 years based on the provided pathology report, we need to analyze the key findings:

1. **Tumor Characteristics**: The report indicates an invasive adenocarcinoma in the left upper lobe, measuring 3.5 cm. The tumor is classified as histologic grade 2/4, which suggests a moderate differentiation. 

2. **Lymph Node Involvement**: The report states that most lymph nodes were free of tumor, but hilar node #2 contained metastatic adenocarcinoma. This indicates that there is some degree of spread, but it is limited to one lymph node.

3. **Invasion**: There is no invasion of the visceral pleura or large vessels, which is a positive sign as it suggests that the tumor has not aggressively spread beyond its local area.

4. **TNM Staging**: The tumor is classified as pT2a (indicating a tumor size between 3-5 cm), pN1 (indicating involvement of regional lymph nodes), and pMX (indicating that distant metastasis cannot be assessed). This staging suggests that the cancer is localized with some regional spread but does not indicate advanced disease.

5. **Resection Margins**: The report confirms that the resection margins were clear of tumor, which is a favorable prognostic factor.

Considering these factors, the presence of a single positive lymph node (pN1) and the absence of visceral pleural invasion or large vessel involvement suggest that the cancer is still manageable and may not significantly impact the patient's survival in the short term.

Based on this analysis, it is reasonable to conclude that the patient has a good chance of survival after 2.48 years.

Answer - {""Survival"": ""True""}"
27,"To determine if the patient will survive after 2.48 years based on the provided pathology report, we need to analyze the key findings:

1. **Tumor Characteristics**: The tumor is diagnosed as adenocarcinoma in the left upper lobe, measuring 3.5 x 2.8 x 2.5 cm. The presence of solid, acinar, and bronchioloalveolar components suggests a complex tumor type, which can influence prognosis.

2. **Invasion**: The tumor invades the visceral pleura, which is a concerning feature as it indicates a more aggressive disease. Pleural invasion is often associated with a higher risk of metastasis.

3. **Metastasis**: There is evidence of metastatic adenocarcinoma in peribronchial lymph nodes. The presence of metastasis in lymph nodes is a significant factor that typically worsens the prognosis.

4. **Vascular and Lymphatic Invasion**: While there is no vascular invasion noted, lymphatic invasion is pending. If lymphatic invasion is confirmed, it could further indicate a higher risk of spread.

5. **Additional Findings**: The report mentions centrilobular emphysema, pulmonary hemosiderosis, and necrotizing granulomas in the lymph nodes, with some lymph nodes showing negative results for neoplasm. While these findings provide additional context, the critical factors for survival are the tumor size, invasion, and metastasis.

Given the tumor's size, pleural invasion, and confirmed metastasis in lymph nodes, the prognosis is likely poor. The presence of metastatic disease significantly impacts survival rates.

Based on this analysis, the conclusion is that the patient is unlikely to survive after 2.48 years.

Answer - {""Survival"": ""False""}"
28,"To determine if the patient will survive after 2.48 years based on the provided pathology report, we need to analyze the key features of the tumor and its implications for prognosis.

1. **Tumor Characteristics**: The tumor is described as a poorly differentiated adenocarcinoma measuring 58 mm. Poorly differentiated tumors generally have a worse prognosis compared to well-differentiated tumors due to their aggressive nature.

2. **Cavitated Tumor**: The presence of cavitation can indicate a more advanced disease, but it is not solely determinative of prognosis.

3. **Visceral Pleural Invasion**: The tumor has invaded the visceral pleura, which is a negative prognostic factor. This suggests that the tumor has a higher likelihood of spreading beyond the lung.

4. **Chest Wall Involvement**: The report indicates involvement of the chest wall, which is significant as it suggests a more advanced stage of cancer (potentially T3 or T4). This is a critical factor that can affect survival negatively.

5. **Margins**: The bronchial resection margin is clear, which is a positive aspect, as it indicates that the tumor has not spread to the bronchial tissue at the surgical margin.

6. **Vascular Invasion**: There is evidence of blood vessel invasion, which is concerning as it can facilitate metastasis to distant sites.

7. **Lymphatic and Perineural Invasion**: The absence of lymphatic or perineural invasion is a positive sign, as these factors can also contribute to a worse prognosis.

8. **Lymph Node Metastases**: Importantly, no lymph node metastases were found, which is a favorable prognostic indicator. However, the other factors (pleural invasion and chest wall involvement) weigh heavily against the prognosis.

In summary, while the absence of lymph node metastases is a positive factor, the presence of visceral pleural invasion, chest wall involvement, and poorly differentiated status of the tumor suggest a more aggressive disease with a poorer prognosis. Therefore, it is likely that the patient may not survive after 2.48 years.

Answer - {""Survival"": ""False""}"
29,"To determine if the patient will survive after 2.48 years based on the provided pathology report, we can analyze the key findings:

1. **Tumor Characteristics**: The tumor is described as poorly differentiated adenocarcinoma, which generally has a worse prognosis compared to well-differentiated tumors. However, the size of the tumor is relatively small at 3.5 x 3 cm.

2. **Lymph Node Examination**: Seven hilar lymph nodes were examined, and all showed reactive changes with no evidence of metastasis. This is a positive indicator, as the absence of metastatic involvement in lymph nodes is associated with a better prognosis.

3. **Surgical Margins**: The report states that the surgical margins are uninvolved, indicating that the tumor was completely resected. Clear margins are crucial for reducing the risk of local recurrence.

4. **Venous Invasion**: There is no evidence of venous invasion, which is another favorable factor, as venous invasion can indicate a higher likelihood of metastasis.

Considering these points, the absence of metastasis in lymph nodes, clear surgical margins, and no venous invasion suggest a more favorable prognosis for the patient. While the tumor is poorly differentiated, the overall findings indicate that the patient has a reasonable chance of survival after 2.48 years.

Based on this analysis, the final answer is:

{""Survival"": ""True""}"
30,"To determine if the patient will survive after 2.48 years based on the provided pathology report, we need to analyze the key findings:

1. **Tumor Characteristics**: The report indicates a solid predominant adenocarcinoma measuring 3.7 cm. This size suggests a significant tumor burden, but it is classified as Stage IIB, which indicates that it is still localized but may have some risk factors for progression.

2. **Lymph Node Involvement**: Importantly, all examined lymph nodes (11 total) are negative for malignancy. This is a favorable sign, as it suggests that the cancer has not spread to the lymphatic system, which is often a critical factor in determining prognosis.

3. **Invasion**: The report states that there is no visceral pleural invasion or lymph-vascular invasion identified. This further supports a more favorable prognosis, as these factors typically indicate a higher risk of metastasis and poorer outcomes.

4. **Stage IIB**: While Stage IIB indicates a more advanced stage than early-stage cancers, the absence of lymph node involvement and invasion suggests that the cancer may still be manageable and potentially treatable.

5. **Ancillary Studies**: The absence of EGFR mutations does not necessarily indicate a poor prognosis, as treatment options may still be available.

Considering these factors, the overall assessment leans towards a more favorable prognosis for survival after 2.48 years, given the absence of metastasis and invasion.

Based on this reasoning, the final answer is:

{""Survival"": ""True""}"
31,"To determine if the patient will survive after 2.48 years based on the provided pathology report, we need to analyze the key findings:

1. **Tumor Characteristics**: The report indicates a poorly differentiated adenocarcinoma measuring 3.5 cm. Poorly differentiated tumors generally have a worse prognosis compared to well-differentiated tumors.

2. **Invasion**: There is evidence of invasion into the visceral pleura and large vessels. This is a significant factor as it suggests a more aggressive disease and a higher likelihood of metastasis.

3. **Lymph Node Involvement**: The report states that there are metastases in the ipsilateral peribronchial and hilar lymph nodes. This indicates that the cancer has spread beyond the primary site, which is a critical factor in staging and prognosis.

4. **Negative Lymph Node Biopsies**: While multiple lymph node biopsies from various stations were negative for malignancy, the presence of metastases in other lymph nodes is concerning and suggests that the cancer is not localized.

5. **Margins**: The bronchial margins are reported as free of tumor with a distance of 5 mm from the invasive carcinoma to the closest margin. This is a positive aspect, but it may not be sufficient to outweigh the other negative factors.

Considering these points, the presence of poorly differentiated adenocarcinoma, visceral pleural invasion, large vessel invasion, and lymph node metastases suggests a poor prognosis. Therefore, it is likely that the patient may not survive after 2.48 years.

Answer - {""Survival"": ""False""}"
32,"To determine if the patient will survive after 2.48 years based on the provided pathology report, we need to analyze the key findings:

1. **Tumor Characteristics**: The tumor is described as poorly differentiated adenocarcinoma measuring 2.5 cm. Poorly differentiated tumors generally have a worse prognosis compared to well-differentiated tumors.

2. **Surgical Margins**: The surgical margins are uninvolved, which is a positive sign indicating that the tumor has been adequately removed without leaving cancerous cells at the edges of the resection.

3. **Visceral Pleural Invasion**: There is a suggestion of visceral pleural invasion. This is concerning as it may indicate a more aggressive disease and a higher likelihood of metastasis.

4. **Lymph Node Involvement**: The report states that two lymph nodes from the lobectomy specimen were negative for metastatic disease, which is favorable. However, it also mentions that only the level 12 nodes demonstrated evidence of metastasis. The presence of metastasis in any lymph node is a negative prognostic factor.

5. **Overall Assessment**: The combination of a poorly differentiated tumor, potential visceral pleural invasion, and the presence of metastasis in lymph nodes suggests a more advanced disease state. While the uninvolved surgical margins are a positive aspect, the other factors weigh heavily against a favorable prognosis.

Considering these points, the overall prognosis appears to be poor due to the aggressive nature of the tumor and the presence of metastasis.

Final Answer - {""Survival"": ""False""}"
33,"To determine if the patient will survive after 2.48 years based on the provided pathology report, we need to analyze the key findings:

1. **Tumor Characteristics**: The tumor is described as poorly differentiated adenocarcinoma measuring 3.5 cm. Poorly differentiated tumors generally have a worse prognosis compared to well-differentiated tumors.

2. **Invasion**: The tumor invades the pleura, which is a concerning feature as it indicates a more aggressive disease. However, the surgical margins are negative for tumor, which is a positive aspect as it suggests that the tumor was completely resected.

3. **Vascular Invasion**: The presence of vascular invasion is another negative prognostic factor, as it can indicate a higher likelihood of metastasis.

4. **Lymph Node Involvement**: Importantly, the report states that there is no evidence of regional lymph node involvement or distant metastasis. This is a significant positive factor, as the absence of metastasis greatly improves the prognosis.

Considering these factors, while the tumor is poorly differentiated and has vascular invasion, the lack of lymph node involvement and distant metastasis suggests that the disease may still be manageable. The negative surgical margins also indicate a successful resection.

Based on this analysis, the overall prognosis leans towards survival, despite the aggressive nature of the tumor.

Answer - {""Survival"": ""True""}"
34,"To determine if the patient will survive after 2.48 years based on the provided pathology report, we need to analyze the key findings:

1. **Tumor Characteristics**: The tumor is described as a 2.8 cm invasive moderately differentiated adenocarcinoma located in the right upper lobe. The size and differentiation of the tumor are important factors in assessing prognosis.

2. **Invasion**: The report indicates angiolymphatic and visceral pleural invasion. Angiolymphatic invasion suggests a higher risk of metastasis, which can negatively impact survival. Visceral pleural invasion also indicates a more aggressive tumor behavior.

3. **Lymph Nodes**: All sampled lymph nodes are reported as benign, which is a positive sign. The absence of metastatic involvement in the lymph nodes is crucial for a better prognosis.

4. **Surgical Margins**: The surgical resection margins are free of tumor, indicating that the tumor was completely removed, which is favorable for survival.

5. **Pathologic Stage**: The tumor is classified as T2N0MX. The T2 classification indicates a larger tumor size (between 2-5 cm) but the N0 classification (no regional lymph node involvement) is a positive prognostic factor.

6. **Additional Findings**: The presence of chronic inflammation and emphysematous changes may indicate underlying lung issues, but they do not directly affect the prognosis of the adenocarcinoma.

Considering these factors, the presence of visceral pleural invasion raises concerns about the aggressiveness of the tumor, but the absence of lymph node involvement and clear surgical margins are significant positive indicators. 

Overall, while the tumor has some aggressive features, the lack of lymph node metastasis and clear margins suggest a better chance of survival.

Based on this analysis, the final answer is:

{""Survival"": ""True""}"
35,"To determine if the patient will survive after 2.48 years based on the provided pathology report, we need to analyze the key findings:

1. **Tumor Type and Differentiation**: The report indicates a diagnosis of poorly differentiated non-small cell carcinoma (NSCLC) originating from the lung. Poorly differentiated tumors generally have a worse prognosis compared to well-differentiated tumors.

2. **Tumor Size**: The maximum tumor size is reported as 5.5 x 5.0 cm. Larger tumors are often associated with a higher stage and worse prognosis.

3. **Unifocality**: The tumor is described as unifocal, which is somewhat favorable compared to multifocal tumors, but the size and differentiation still raise concerns.

4. **Lymph Node Involvement**: Importantly, all examined lymph nodes were negative for carcinoma. This is a positive sign, as the absence of lymph node involvement typically indicates a better prognosis.

5. **Immunohistochemical Staining**: The positive TTF-1 and negative results for other markers support the diagnosis of adenocarcinoma, which is relevant for treatment decisions but does not directly influence survival in this context.

6. **Pending Further Characterization**: The report mentions that further characterization of the tumor type is pending additional immunoevaluation. This uncertainty could impact treatment options and prognosis, but the current findings are what we must base our decision on.

Considering these factors, the absence of lymph node involvement is a significant positive indicator for survival, despite the poorly differentiated nature and size of the tumor. 

Based on the analysis, the patient has a reasonable chance of survival after 2.48 years due to the lack of lymph node metastasis, despite the other concerning factors.

Answer - {""Survival"": ""True""}"
36,"To determine if the patient will survive after 2.48 years based on the provided pathology report, we need to analyze the key findings:

1. **Tumor Characteristics**: The report indicates a poorly differentiated adenocarcinoma measuring 7 cm. Poorly differentiated tumors generally have a worse prognosis compared to well-differentiated tumors, but size alone is not the only factor.

2. **Margins**: The report states that there is no invasion of the visceral pleura and that the bronchial and vascular margins are negative. This is a positive sign, as it indicates that the tumor has been successfully resected without leaving cancerous cells at the margins.

3. **Lymph Node Involvement**: All examined lymph nodes from levels 4, 7, and 9 showed no evidence of tumor. This is crucial because the absence of metastatic spread to lymph nodes is a strong indicator of a better prognosis.

4. **Overall Findings**: The combination of clear margins and no lymph node involvement suggests that the cancer has not spread beyond the primary site, which is a favorable outcome.

Considering these points, the prognosis appears to be positive due to the successful resection and lack of metastasis. Therefore, it is reasonable to conclude that the patient has a good chance of survival after 2.48 years.

Answer - {""Survival"": ""True""}"
37,"To determine if the patient will survive after 2.48 years based on the provided pathology report, we need to analyze the key findings:

1. **Tumor Characteristics**: The tumor is a mixed acinar and bronchioloalveolar adenocarcinoma measuring 3.5 cm. The differentiation is moderate to poor, which generally indicates a more aggressive tumor behavior.

2. **Lymph Node Involvement**: Metastatic adenocarcinoma was found in one of the two resected lymph nodes. This is significant because lymph node involvement typically suggests a higher stage of cancer and can correlate with a poorer prognosis.

3. **Negative Lymph Nodes**: While the remaining lymph nodes were negative for tumor, the presence of metastasis in one lymph node is still concerning.

4. **KRAS Mutation**: The positive KRAS mutation analysis indicates a mutation in the KRAS gene, which is often associated with a more aggressive form of cancer and can influence treatment options and prognosis.

Considering these factors, the presence of a moderately differentiated tumor, lymph node metastasis, and a KRAS mutation suggests a higher risk of disease progression and potentially a lower chance of survival over the specified time frame.

Based on this analysis, the conclusion is that the patient is likely to have a poor prognosis.

Answer - {""Survival"": ""False""}"
